Peri- and postinterventional antithrombotic therapy in TAVI

Summary

Interventional treatment of aortic valve stenosis by transcatheter aortic valve replacement (TAVR) has become routine practice in elderly and high risk patients in recent years. Similar to other vascular interventional or surgical procedures TAVR carries thrombotic risks such as stroke, myocardial infarction or systemic embolism as well as peri-procedural bleeding risks. These risks comprise the access site, the type of prosthesis, and the individual risk profile of the patient. Not only during the peri-procedural period but also during longterm follow-up the current target population for TAVR procedures carries a high risk for thrombotic events in particular if atrial fibrillation is present. On the other hand side the bleeding risk is also increased in these patients. Thus, to provide the optimal strategy of antithrombotic therapy during and after TAVR remains a clinical challenge.

Zusammenfassung

Die interventionelle Therapie der Aortenklappenstenose ist in den vergangenen Jahren zu einem Routineverfahren geworden. Wie auch bei anderen intravaskulären Verfahren besteht hierbei ein Thromboembolie- und ein Blutungsrisiko, das jeweils sowohl vom Patienten als auch von der Prozedur anhängt. Daher bleibt es eine klinische Herausforde-rung den optimalen Grad der antithrombotischen Therapie zu wählen.

Keywords

Transcatheter aortic valve replacement

Schlüsselwörter

TAVI - antithrombotic therapy

• References

• 1 Genereux P, Head SJ, Van Mieghem NM. et al. Clinical outcomes after transcatheter aortic valve replacement using valve academic research consortium definitions: A weighted meta-analysis of 3,519 patients from 16 studies. J Am Coll Cardiol 2012; 59: 2317-2326.
• 2 Rodes-Cabau J, Dauerman HL, Cohen MG. et al. Antithrombotic treatment in transcatheter aortic valve implantation: Insights for cerebrovascular and bleeding events. J Am Coll Cardiol 2013; 62: 2349-2359.
• 3 Amat-Santos IJ, Rodes-Cabau J, Urena M. et al. Incidence, predictive factors, and prognostic value of new-onset atrial fibrillation following transcatheter aortic valve implantation. J Am Coll Cardiol 2012; 59: 178-188.
• 4 Vahanian A, Alfieri O, Andreotti F. et al. Guidelines on the management of valvular heart disease (version 2012). Eur Heart J 2012; 33: 2451-2496.
• 5 Nishimura RA, Otto CM, Bonow RO. et al. 2014 aha/acc guideline for the management of patients with valvular heart disease. Circulation 2014; 129: 2440-2492.
• 6 Whitlock RP, Sun JC, Fremes SE. et al. Antithrombotic and thrombolytic therapy for valvular disease. Chest 2012; 141: e576S-e600S.
• 7 Windecker S, Kolh P, Alfonso F. et al. 2014 ESC/ eacts guidelines on myocardial revascularization. Eur Heart J 2014; 35: 2541-2619.
• 8 Leon MB, Smith CR, Mack M. et al. Transcatheter aortic-valve implantation for aortic stenosis in patients who cannot undergo surgery. N Engl J Med 2010; 363: 1597-1607.
• 9 Smith CR, Leon MB, Mack MJ. et al. Transcatheter versus surgical aortic-valve replacement in high-risk patients. N Engl J Med 2011; 364: 2187-2198.
• 10 Adams DH, Popma JJ, Reardon MJ. et al. Transcatheter aortic-valve replacement with a self-expanding prosthesis. N Engl J Med 2014; 370: 1790-1798.
• 11 Durand E, Blanchard D, Chassaing S. et al. Comparison of two antiplatelet therapy strategies in patients undergoing transcatheter aortic valve implantation. Am J Cardiol 2014; 113: 355-360.